PandaOmics is a cloud-based software platform that applies artificial intelligence and bioinformatics techniques to multimodal omics and biomedical text data for therapeutic target and biomarker ...
When Insilico Medicine’s CEO Alex Zhavoronkov, PhD, and his co-authors wrote their 2023 opinion paper on AI-powered target discovery, 1 he was thinking about how often target discovery is ...
New publication demonstrates that insitro’s POSH platform — integrating pooled CRISPR screening and self-supervised deep learning — successfully breaks the historic compromise between scale and depth ...
Disease modeling and target identification are critical and time-consuming portions of the drug discovery process and areas where artificial intelligence (AI) is already making a substantial impact. A ...
Insilico Medicine leverages AI to identify promising new target for breast and gynecological cancers
Insilico Medicine("Insilico"), a clinical stage generative artificial intelligence (AI)-driven drug discovery company, recently published an early research that it has identified MYT1 as a promising ...
Drug discovery has long relied on two key strategies: target-based and phenotypic screening. Recombinant technologies and genomics opened the door to modern target-based drug discovery (TBDD), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback